Sexually Transmitted Diseases (STD) Testing Market Expected to reach $1,50,445.01 Million by 2030 | CAGR of 5.1%

According to a new report published by Allied Market Research, titled, “STD Testing Market by Disease Type and Location of Testing: Global Opportunity Analysis and Industry Forecast, 2021-2030,” The sexually transmitted diseases testing market accounted for $91,445.93 Million in 2020, and is expected to reach $1,50,445.01 Million by 2030, registering a CAGR of 5.1% from 2021 to 2030.

The STD market growth is strongly driven by high incidence rates and increase in prevalence rates of STDs such as chlamydia, syphilis, and gonorrhea. Moreover, implementation of national screening programs to improve and increase the STD diagnosis in many key geographies such as U.S., UK, Canada, and support in reimbursement for STDs testing are further supporting the sexually transmitted diseases (STD) testing market growth. However, there is social stigma associated with patients visiting specialized STD clinics which refrain patients from STD diagnosis. Moreover, huge proportion of patients infected with STDs are based in out-of-reach geographic areas which significantly limits the diagnosis of STDs. Such factors are expected to restrain the STD testing market growth.

At present, STDs are considered as one of the most critical health challenges globally. Chlamydia, gonorrhea, and herpes simplex virus are some of the highly prevalent STDs. The STD testing market has gained prominence in the recent years due to high prevalence of major STDs worldwide and as a result, increase in need for STD diagnosis. However, limited access to STD diagnosis in majority of the population from developing regions is expected to restrain the sexually transmitted diseases (STD) testing market growth.

By disease type, the chlamydia testing segment is the highest revenue contributor and gonorrhea segment is expected to exhibit the fastest growth rate of 7.3%. This is attributed to the increased prevalence of gonorrhea in the last decade.

This report provides comprehensive competitive analysis and profiles of prominent market players such as Abbott laboratories, Becton Dickinson Company, BioMérieux, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Diasorin Molecular LLC, Hologic, Inc., Orasure Technologies, Inc., Roche Holding AG and Thermo Fisher Scientific Inc.

Key Findings of the Study

• By intubation, the orotracheal intubation segment held the largest sexually transmitted diseases (STD) testing market share in 2020 and is expected to remain dominant during the forecast period.
• By application, the anesthesia segment held the largest market share in 2020 and is expected to remain dominant during the forecast period.
• By end user, the hospitals segment held the largest sexually transmitted diseases testing market share in 2020 and is expected to remain dominant during the forecast period.

By region, North America is expected to experience market growth at the highest rate, registering a CAGR of 6.4% during the forecast period.